Research

Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR)

Carmen Aceves , Pablo García-Solís , Omar Arroyo-Helguera , Laura Vega-Riveroll , Guadalupe Delgado and Brenda Anguiano

Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus UNAM-Juriquilla, Querétaro, 76230, México

author email corresponding author email

Molecular Cancer 2009, 8:33doi:10.1186/1476-4598-8-33

Published:	6 June 2009

Abstract

Introduction

Studies in mammary cancer demonstrated that moderately high concentrations of molecular iodine (I₂) have a antiproliferative and apoptotic effect either in vivo as in vitro, however the cellular intermediated involved in these effects has not been elucidated.

Methods

Virgin Sprague-Dawley rats were treated with methyl-nitrosourea (MNU: single dose ip, 50 mg/Kg bw) and the participation of arachidonic acid (AA) and PPAR receptors in the antineoplasic effect of I₂ where analyzed.

Results

I₂-treated rats for four weeks exhibited a significant reduction in the incidence (62.5 vs. 100%) and size (0.87 ± 0.98 vs 1.96 ± 1.5 cm³) of mammary tumors. HPLC analysis showed that tumoral but not normal mammary tissue contained an elevated basal concentration of AA and significantly more AA-iodinated called 6-iodolactone (6-IL) after chronic I₂ treatment. Tumors from I₂-treated rats showed fewer cells positive to proliferating cell nuclear antigen, lower blood vessel density, as well as decreases in vascular endothelial growth factor, urokinase-type plasminogen activator, and PPAR type alpha (PPARα). These same tumors showed increases in the cell death markers, TUNEL-positive cells (p < 0.05) and the enzyme caspase-3 (trend), as well as significant induction of PPAR type gamma (PPARγ).

Conclusion

Together, these data demonstrate that the antineoplasic effect of iodine involves 6-IL formation and PPARγ induction.